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Extracellular vesicles (EV), including exosomes and microvesicles, are nano-sized intercellular commu-
nication vehicles that participate in a multitude of physiological processes. Due to their biological
properties, they are also promising candidates for the systemic delivery of therapeutic compounds, such
as cytokines, chemotherapeutic drugs, siRNAs and viral vectors. However, low EV production yield and
rapid clearance of administered EV by liver macrophages limit their potential use as therapeutic vehicles.
We have used a hollow-fiber bioreactor for the efficient production of bioactive EV bearing the heter-
odimeric cytokine complex Interleukin-15:Interleukin-15 receptor alpha. Bioreactor culture yielded ~40-
fold more EV per mL conditioned medium, as compared to conventional cell culture. Biophysical analysis
and comparative proteomics suggested a more diverse population of EV in the bioreactor preparations,
while serum protein contaminants were detectable only in conventional culture EV preparations. We
also identified the Scavenger Receptor Class A family (SR-A) as a novel monocyte/macrophage uptake
receptor for EV. In vivo blockade of SR-A with dextran sulfate dramatically decreased EV liver clearance in
mice, while enhancing tumor accumulation. These findings facilitate development of EV therapeutic
methods.
Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://
creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Extracellular vesicles (EV), including exosomes and micro-
vesicles, are nano-sized membrane vesicles secreted by most cell
types. Given their intrinsic properties, e.g. immunomodulation [1,2]
and their ability to distribute systemically, EV are being developed
as biocompatible, targeted therapeutic particles [3,4]. Techniques
to load bioactive cargo, such as protein [5,6], siRNA [7], viral vectorslakis).
access article under the CC BY-NC[8], and chemotherapeutics [9] are also currently investigated in
several settings.
EV for therapeutic applications are typically purified from cell
culture conditioned media of cell lines or primary cells. Purification
methods are comprised of combinations of techniques, including
ultracentrifugation, filtration, precipitation, and chromatography
[10e12], each resulting in somewhat different mixtures of EV
species and non-EV contaminants. Reported EV yields range from 1
to 10 mg/mL culture supernatant, even from “high-yield” systems,
such as the Integra CELLine bioreactor [7,13,14]. Thus, obtaining
sufficient material for in vivo studies currently comprises a-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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of the purification method.
With regard to systemic delivery of EV, modifying surface pro-
teins with targeting ligands has enabled increased delivery to the
CNS (via the RGD targeting peptide) [3] and to EGFR-expressing
tumors (via the GE11 peptide) [15]. However, systemically deliv-
ered EV are rapidly cleared by the monocyte/macrophage or
reticuloendothelial system (RES), resulting in minimal accumula-
tion within the desired target sites [4,15e19], which is a major
hurdle for EV-based systemic therapeutic approaches. Depletion of
monocytes/macrophages was shown to significantly prolong EV
systemic half-life in mice, suggesting uptake by these cells as an
important mechanism of EV clearance in vivo [17]. Clearance of
synthetic nanoparticles by the RES was shown to be largely medi-
ated by the Scavenger Receptor Class A family (SR-A), which rec-
ognizes a variety of negatively charged ligands, including
phosphatidylserine [20], a phospholipid shown to be enriched on
EV. Indeed, masking phosphatidylserine with annexin-V decreased
EV uptake in vitro [21].
Herein, we describe approaches to overcome obstacles of EV
production and delivery, which will facilitate further development
of this therapeutic platform. We compare EV production using an
efficient hollow-fiber culture system to that of conventional culture
methods. We show that this method produces bioactive EV
retaining surface proteins and can be used for the production of
bioactive, EV associated heterodimeric interleukin-15. We also
identify SR-A as a major receptor for the clearance of EV by
monocyte/macrophages, and assess the applicability of SR-A
blockade to achieve tumor delivery of administered EV in mice.
2. Materials and methods
2.1. Cells
HEK293 and all mouse cell lines (RAW264.7, 4T1, B16, LLC1,
MC38 and EG.7) were obtained fromATCC. HEK293 cells expressing
high levels of hetIL-15 were previously described [22,23]. NK92
cells were kindly provided by Dr. Howard A. Young (Cancer and
Inflammation Program, National Cancer Institute, USA). Blood
samples from healthy blood donors were collected in acid-citrate-
dextrose tubes, under approved protocols for human subjects'
research by the National Cancer Institute Investigational Review
Board. Peripheral bloodmononuclear cells (PBMC) were purified by
gradient centrifugation over Histopaque-1077 (Sigma-Aldrich),
according to the manufacturer's protocol.
4T1 cells were cultured in RPMI 1640 medium supplemented
with 10% fetal calf serum. RAW264.7 and E.G7 cells were cultured in
RPMI 1640 medium, supplemented with 5% fetal calf serum. The
remaining cell lines were cultured in DMEM medium, supple-
mented with 10% fetal calf serum.
Human PBMC were cultured overnight in RPMI medium sup-
plemented with 10% fetal calf serum and 100 U/mL penicillin/
streptomycin. The cells were used within 24 h of purification from
whole blood.
2.2. Cell culture method for EV production
EV/protein aggregate depleted cell culture medium was ob-
tained by ultrafiltration of complete medium through a 500 kDa
commercial hollow fiber ultrafiltration module (mPES MidiKros
500 kDa filter module, Spectrum Laboratories; Rancho Dominquez,
CA), as previously described [14,24]. Specifically, a peristaltic pump
was used to slowly circulate culture medium through the filter
module, and filtrate was collected to be used as EV/protein aggre-
gate depleted medium. The entire procedure was carried out usingsterile materials within a biosafety cabinet. Ultrafiltered superna-
tant was filtered a second time through a 0.22 mm filter device to
ensure sterility.
To obtain conditioned medium from conventional cultures, 3
million cells were seeded in 175 cm2 tissue culture flasks in DMEM
supplemented with 10% fetal calf serum and 100 U/mL penicillin/
streptomycin. After overnight incubation, cell monolayer was
gently washed with PBS, and 15 mL of fresh EV/protein aggregate-
depleted medium was added to each flask. 48 h later, conditioned
medium was harvested and pooled for immediate EV purification.
After conditionedmediumwas removed, cells were collected in PBS
and pelleted by centrifugation at 300  g. Cell lysates were pre-
pared by addition of N1 lysis buffer to cell pellet, incubation on ice
for 1 h, and two rounds of sonication for 6 s.
2.3. Fibercell hollow-fiber bioreactor culture
The HEK293 cell clone stably expressing hetIL-15 (clone 19.7)
was expanded in conventional culture flasks and used to seed a
medium-sized, hollow-fiber culture cartridge, with a 20 kDa mo-
lecular weight cut-off (Fibercell Systems; Frederick, MD). Cells were
adapted over two weeks to bioreactor culture conditions by
gradually increasing the proportion of protein-free medium
(DMEM þ 10% Fibercell Systems CDMHD protein-free
supplement þ 100 U/mL penicillin/streptomycin). Bioreactor
conditioned medium (20 mL) was collected for each harvest three
times per week. Harvests were cleared of cells by 300  g centri-
fugation, and supernatants stored at80 C for further purification.
2.4. EV purification
After removing large cell debris by centrifugation at 3000  g
for 15 min, the supernatants were carefully moved to poly-
carbonate tubes, and spun for 45 min at 20,000  g in a type 45Ti
rotor (Beckman-Coulter; Brea, CA). Supernatants were then filtered
through 0.22 mm Stericup device (EMD Millipore; Billerica, MA),
moved to Snakeskin 10 kDa MWCO dialysis tubing (Thermo-
Scientific; Grand Island, NY), and dialyzed overnight in >30 vol-
umes of Tris-buffered saline (TBS). Dialyzed supernatants were
centrifuged for 2 h at 110,000  g in a type 70.1Ti rotor (Beckman-
Coulter) to pellet EV. Pellets were resuspended to the original
volume in TBS, by passing through a 27G needle approximately 5
times (until aggregates were no longer visible), and centrifuged
again at 110,000  g to wash away contaminating soluble proteins.
EV pellets were resuspended in 1/50 original volume of TBS
following the procedure described above. Finally, EV were addi-
tionally cleared of residual aggregation by 3 min centrifugation at
20,000  g in a microfuge, and the supernatants containing the EV
were transferred to a clean Lobind protein tube (Eppendorf;
Hauppauge, NY), and stored at 80 C for downstream applica-
tions. All purification steps were conducted at 4 C.
For experiments directly comparing conventional culture to
bioreactor EV, conditioned cell culture media were concentrated by
ultrafiltration (Centricon-70, 100 kDa MWCO; EMDMillipore) prior
to 110,000  g centrifugation. This allowed for a larger volume of
conventional flask-derived supernatants to be pooled prior to ul-
tracentrifugation. Furthermore, initial EV pellet was not washed,
but rather immediately resuspended in 100 mL TBS. These protocol
modifications were implemented to allow for sufficient EV yields
from conventional flask supernatants for downstream comparison
analyses.
2.5. Biophysical characterization and imaging
Nanoparticle tracking analysis (NTA) was performed on fresh
D.C. Watson et al. / Biomaterials 105 (2016) 195e205 197and freeze-thawed EV samples in triplicate using a Nanosight LM10
(Malvern Instruments; Malvern, United Kingdom) to estimate size
distribution (hydrodynamic diameter), particle concentration, and
effects of freeze-thawing (Fig. S1). Samples were diluted to 1e2 mg/
mL in PBS, and 3 videos of 30 s were acquired for each triplicate.
Dynamic light scattering (DLS) was performed on a nanoparticle
analyzer SZ-100 (Horiba Scientific) at the same dilution.
For transmission electronmicroscopy (TEM) sample preparation
and imaging, EV suspensions were fixed with 2% glutaraldehyde
(Electron Microscopy Sciences, Cat#16020) and then adsorbed to
formvar/carbon coated TEM copper grids (SPI, Cat#3420C-MB).
Samples were then negative stained with 1% Uranyl Acetate
(Electron Microscopy Sciences, Cat# 22400) for 10 s. The samples
were evaluated on a JEOL 1011 transmission electron microscope at
80 kV, and digital images were acquired using AMT camera system.
2.6. EV protein composition determination
Purified EV preparations were monitored for protein content by
the Bradford assay, using bovine gamma-globulin as a standard.
Specifically, 5 mL of EV preparation was added to 250 mL Quickstart
Bradford reagent (Bio-Rad; Hercules, CA), and incubated for
15 min at room temperature. Protein concentration was quantified
by measuring absorbance at 595 nm on a microplate reader.
For Western blots, EV were lysed by adding 5 RIPA buffer and
incubating on ice for 45 min. Antibodies used to probe the blots
included: aCD63 (System Biosciences; Mountain View, CA), aAlix
(clone 3A9, LifeSpan Biosciences; Seattle, WA), aIL-15 (AF315, R&D
Systems) and aIL-15Ra (AF247, R&D Systems). All blots were pro-
bed overnight at 4 C.
Detection of EV-associated IL-15 was performed by flow
cytometry using the ExoFlow kit (System Biosciences) according to
manufacturer's protocol. Briefly, 9.1 mm streptavidin-coated mag-
netic beads were loaded with biotinylated anti-CD63 exosome
capture antibody. Next, 100 mg of purified EV were incubated
overnight at 4 C with antibody-loaded beads in a rotating micro-
tube holder. EV-loaded magnetic beads were then washed using a
magnetic tube stand, and divided for staining with individual
fluorophore-conjugated antibodies: FITC-lectin (provided in kit)
and PE-conjugated anti-IL-15 (clone 34559; R&D Systems, Minne-
apolis, MN). Incubation with antibodies was for 2 h on ice, gently
flicking the tube to resuspend beads every 30min. Finally, unbound
antibody was washed from beads using a magnetic tube stand, and
EV-loaded beads were acquired on a flow cytometer (LSR-II; BD
Biosciences, Franklin Lakes, New Jersey).
2.7. Comparative proteomics study
5 RIPA buffer was added to EV samples (~20 mg), and incubated
for 30 min on ice to lyse EV. Samples were then mixed with LDS gel
loading buffer and NuPAGE sample reducing agent (Invitrogen),
heated at 96 C for 10 min, then, loaded on a 4e12% NuPAGE gel
(Invitrogen). After two hours of running at a constant voltage
(100 V), the gel was stained with SimplyBlue Safestain (Invitrogen).
Each gel lane was excised into 12 gel slices. The gel slices were in-
gel digested individually with Trypsin (Promega) at 37 C over-
night. Each digested peptide sample was desalted by C18 ZipTip
(Millipore), lyophilized and re-suspended in 0.1% formic acid for
LC-MS analysis. Each sample (6 mL) was loaded on an Easy nLC II
nano-capillary HPLC system (Thermo Scientific) with a C18 Nano
Trap Column, (Acclaim PepMap100 C18, 2 cm, nanoViper, Thermo
Scientific) and an analytical column (Acclaim PepMap RSLC C18,
15 cm, nanoViper, Thermo Scientific) connected with a stainless
steel emitter, coupled online with a Q Exactive hybrid OrbiTrap
mass spectrometer (Thermo Scientific) for RPLC-MS/MS analysis.Peptides were eluted using a linear gradient of 2% mobile phase B
(acetonitrile with 0.1% formic acid) to 42% mobile phase B within
70 min at a constant flow rate of 200 nL/min. The twelve most
intense molecular ions in the MS scan were sequentially selected
for high-energy collisional dissociation (HCD) using a normalized
collision energy of 30%. The mass spectrawere acquired at the mass
range of m/z 300e2000. The Easy Nano Spray ion source (Thermo
Scientific) capillary voltage and temperature were set at 1.7 kV and
275 C, respectively. The dynamic exclusion function on the mass
spectrometer was enabled during the MS2 data acquisition. The MS
data were searched against the UniProt Homo sapiens database
downloaded from the European Bioinformatics Institute website
(http://www.ebi.ac.uk/integr8, January, 2016) utilizing Proteome
Discoverer 1.4 (Thermo Scientific). Up to two missed tryptic
cleavage sites was allowed during the database search. Oxidation
(þ15.9949 Da) of methionyl residue was included as dynamic
modifications. The data was searched with a precursor ion toler-
ance of 20 ppm and a fragment ion tolerance of 50 ppm. The
peptide identifications are filtered through protein percolator with
the cutoff of a false peptide discover rate (FDR) less than 1% for all
peptide identified. “Strict Maximum Parsimony Principle” was
applied during the data compiling.
For comparative analysis of bioreactor vs. flask EV, peak area of
peptide mappings (grouped by corresponding gene) were consid-
ered. Data were normalized to total peak area, using a normaliza-
tion factor of 1.15.
2.8. Bioactivity assay
NK92 cells used for the IL-15 bioactivity assay were cultured in
RPMI 1640medium supplemented with 10% fetal calf serum,100 U/
mL penicillin/streptomycin, 200 U/mL recombinant IL-2 (National
Cancer Institute), and 10 ng/mL hetIL-15 (Admune Therapeutics,
Danvers, MA). Cell density was adjusted three times a week to a
concentration of 3e4  105 cells/ml.
Purified EV were mixed with an equal volume of lysis buffer (1%
Triton-X 100/200 mM Tris-HCl, pH7.4) and lysed by five freeze/
thaw cycles. The amount of EV-associated IL-15 was assessed by
ELISA (Human IL-15 Quantikine ELISA kit; R&D Systems, Minne-
apolis, MN) according to the manufacturer's instructions.
The bioactivity of EV-associated hetIL-15 was assessed on the
human NK-92 cell line, which responds to IL-15 treatment by
proliferating in a dose-dependent manner. NK-92 cells were
cultured overnight at a concentration of 4  105 cells/mL in
cytokine-free media prior to assay use. 50 mL of cytokine-starved
NK-92 cells (4  105 cells/mL) were seeded in each assay well of
96-well plates. hetIL-15 purified protein standard (Admune Ther-
apeutics) and purified EV samples were used to prepare solutions
containing 0.05e2 ng/mL IL-15 (measured as single chain content)
in complete cell culture medium; 50 mL of each IL-15 protein or EV
solution was then added to the corresponding cell culture wells.
Equal amounts of EV lacking IL-15 were used as negative control.
After 72 h incubation, 25 mL MTT labeling reagent (Roche, Indian-
apolis, IN) was added to each well, and plates incubated for 5 h at
37 C. Next, 100 mL solubilization buffer (10% SDS in 0.01 M HCl;
Roche) was added to each well, and plates incubated for 24 h at
37 C. Optical density of samples was measured at 570/690 nm,
using a SpectraMax Plus 384 microplate reader (Molecular Devices,
Sunnyvale, CA).
2.9. EV labeling for in vitro and in vivo tracking
Two different labeling dyes were used to monitor EV uptake: a
green RNA dye (Syto RNASelect Green; Invitrogen, Grand Island,
NY), and a near-infrared lipid dye (DiOC18(7) or DiR; Invitrogen).
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incubated with the dye at a final concentration of 10 mM for
30 min at 37 C. For DiR staining, 62.5 mg EV in 100 mL TBS were
incubated with the dye at a final concentration of 100 ng per
microgram of EV for 1 h at 37 C. After incubation, unincorporated
dye was removed by gel filtration using PBS-hydrated Exosome
Spin Columns (3 kDa MWCO, Invitrogen) (See Supplementary
Fig. S7).
We also checked the stability of DiR staining of EV over 24 h
(Fig. S8). DiR-stained EV were prepared as above, and incubated for
24 h at 37 C. We then repeated the gel filtration procedure to
remove any dye that may have become unincorporated from EV
during the 24 h incubation. For comparison, we prepared freshly
stained EV as above, and immediately performed a second gel
filtration to account for EV losses in the Exosome Spin Columns.
Stained EV from these samples were diluted 1:2, and 60 mL loaded
in each well of a black-walled 96-well plate. Fluorescence intensity
analysis of samples was performed in triplicate using the Odyssey
Classic infrared imaging system (Li-Cor, Lincoln, NE) at the 800 nm
channel.
2.10. In vitro SR-A blockade and EV uptake assessment
For EV uptake blocking experiments, mouse cells were first
plated at a density of 250,000 cells per well in a 12-well plate and
cultured overnight. E.G7 is a suspension cell line and 250,000 cells
were used for each experimental sample. Cells were pre-treated for
30 min with fresh RPMI supplemented with 5% fetal calf serum
medium, containing 100 mg/mL chondroitin sulfate, 100 mg/mL
dextran sulfate or 10 mM BLT-1 (all EV-uptake blocking reagents
obtained from Sigma-Aldrich, St. Louis, MO). Cells were washed
once and incubated with fluorescently labeled EV for 2 h. The cells
were harvested, washed, and resuspended in PBSþ2% bovine
serum albumin for the analysis of EV uptake by flow cytometry. The
EV concentrations used in these experiments were adjusted to
obtain 2e4 fold increase in the fluorescent signal above the auto-
fluorescence from untreated cells (RAW 3.2 mg/mL; 4T1, MC38 and
EG7: 1.6 mg/mL; LLC1 and B16: 0.8 mg/ml).
PBMC were cultured at 2  106 cells/mL and pretreated for
30 min with 500 mg/mL dextran sulfate, 500 mg/mL chondroitin
sulfate, or left untreated. After washing, the cells were resuspended
at a density of 4  106 cells/mL and incubated for 2 h with Syto
RNASelect Green-labeled EV at a final concentration of 800 ng EV
per mL, in a final volume of 0.5 mL. Finally, the cells werewashed in
PBSþ0.2% ABþ human serum and stained with fluorophore-
conjugated antibodies before flow cytometric analysis.
The following antibodies were used: aCD3-APC-Cy7 (clone SK7;
BD Biosciences), aCD4-V500 (clone RPA-T4; BD Biosciences), aCD8-
Alexa Fluor 405 (clone 3B5, Invitrogen), aCD14-PE (clone M5E2; BD
Biosciences), aCD14-BV421 (clone HCD14; Biolegend; San Diego,
CA), aCD19-Alexa Fluor 700 (clone HIB19; BD Biosciences), aCD56-
APC (clone B159; BD Biosciences), and aCD204-PE (clone REA460;
Miltenyi Biotec; San Diego, CA).
2.11. In vivo EV biodistribution in tumor-free and tumor-bearing
mice after SR-A blockade
All animal experiments were conducted in compliance with the
guidelines for the care and use of research animals established by
the Animal Studies Committee of the National Institutes of Health.
FVB or Balb/c mice were treated with the SR-A inhibitor dextran
sulfate or chondroitin sulfate (negative control) at a dose of 30 mg/
kg delivered in 100 mL PBS by tail vein injection. Control mice
received 100 mL of PBS intraperitoneally. Two hours later, the mice
received 100 mL of PBS containing 15 mg of DiR stained EV via the tailvein. Imaging of live mice was performed at various time points,
between 1 and 24 h post injection. Some mice were euthanized at
different time points and their organs imaged ex vivo. Imaging was
done on a Maestro™ 2 imaging system (Perkin Elmer).
For tumor inoculation studies, 1  106 4T1 cells in 100 mL of
serum-free medium were implanted subcutaneously on the right
front flank of female BALB/c mice. Once the tumor size reached a
volume of 90e100 mm3, the animals were used for in vivo imaging
experiments.
2.12. Statistical analyses
EV preparation purity and monocyte uptake of EV in vitro were
analyzed using t-tests. EV preparation yield, along with liver,
plasma, and tumor uptake (imaged ex vivo) were analyzed by 1-
way ANOVA. Time courses of in vivo EV uptake by tumor and
liver were analyzed with 2-way ANOVA. All statistical analyses
were performed in Prism 6 (GraphPad Software, La Jolla, CA).
3. Results
3.1. High-yield EV production from hollow fiber bioreactor
In an effort to increase production yield, we used a lab-scale
hollow-fiber bioreactor with protein-free culture medium to
obtain conditioned cell culture supernatants as a source of EV.
Hollow-fiber culture systems can sustain large numbers (>109) of
cells, and produce highly concentrated cell culture supernatants
from a variety of cells, including primary human cells [25,26]. We
hypothesized that these characteristics would facilitate high-yield
production and purification of EV.
HEK293 cells were adapted for growth in a hollow-fiber biore-
actor using serum-free medium (Fig. 1A). EV from bioreactor or
conventional tissue culture flask supernatants were purified by
differential centrifugation, and the protein concentration of the
purified materials was determined using the Bradford assay. Using
a similar protocol of EV purification, bioreactor-harvested condi-
tioned media yielded approximately 5-fold more EV compared to
conventional flasks (Fig. 1B). Further optimization of the EV puri-
fication method, by omitting the supernatant concentration step,
increased the EV yield about two-fold, resulting in a total 10
improved EV yield from cell culture conditioned media (Fig. 1B).
NTA was used to estimate the particle to protein amount ratio, an
indicator of EV purity [7,27]. We found a ratio of 1.09  109
(±2  108 particles)/mg of protein in EV preparations from the
bioreactor, which is ~4-fold greater than the purity of preparations
from our conventional cell culture (Fig. 1C), higher than has pre-
viously been reported for EV obtained from HEK293 cells [7]. EV
markers CD63 and Alix were also enriched in preparations from
bioreactor harvests, supporting increased purity (Fig. 1D). DLS (see
Supplementary Fig. S2) and NTA (Fig. 2A), showed the majority of
purified EV to be between 40 and 200 nm in diameter. TEM showed
well-defined particles of comparable size (Fig. 2b). Together these
data suggest that the use of hollow-fiber bioreactor, serum-free
media and an optimized purification protocol represent a supe-
rior method to achieve high yield of purified EV (yields were
>3 mg/week from a single lab-scale culture cartridge).
3.2. Comparison of bioreactor to flask-derived EV characteristics
We observed that the relative enrichment of CD63, as detected
by Western blot (Fig. 1D), could not be fully accounted for by the
increased particle purity of the bioreactor EV preparations. We
therefore conducted an in-depth comparison of the particles pu-
rified from either source to assess whether the bioreactor
Fig. 1. Hollow-fiber bioreactor is a high-yield source of EV. (A) Schematic representation of EV production in hollow-fiber bioreactor. Fresh medium is pumped through the cell
culture cartridge cylinder. Medium circulates within the hollow fibers of the culture cartridge, and (*) nutrient/waste exchange occurs through the hollow-fiber wall pores (20 kDa
MWCO). Larger molecular weight cellular products (including EV) accumulate within the extracellular space of the cell culture cartridge cylinder. The extracellular space medium
containing large amounts of EV is harvested every 1e3 days. (B) Yield of EV preparations from a hollow fiber bioreactor is ~10-fold more than conventional flask conditioned media.
EV were purified from bioreactor conditioned media either by an optimized protocol (filtration, dialysis, and differential centrifugation) or by a protocol for direct comparison to
conventional flask culture (ultrafiltration to concentrate conditioned media, filtration, and differential centrifugation). Protein yield, calculated as mg EV-associated protein per
milliliter original conditioned medium (mean ± SEM), was quantified in independent preparations, and compared by ANOVA (*p < 0.05; ***p < 0.001). (C) Particle purity of EV
preparations from a hollow fiber bioreactor is ~4-fold higher than conventional flask conditioned media. Particle purity indicates the level of EV-free protein contamination of EV
preparations, and was assessed as the number of particles per mg protein, as measured by nanoparticle tracking analysis. (D) Enrichment of EV-associated markers in western blot of
bioreactor EV preparations vs. conventional flask culture suggests higher purity. Each lane was loaded with 20 mg total protein, and band intensity quantification was performed by
densitometry. In bioreactor EV preparations, we also observed differentially processed forms of associated proteins. In the case of CD63, lower molecular weight bands may reflect
differential glycosylation pattern, as this protein has several glycosylation modifications. For Alix, there are several known phosphorylation sites, whose differential status could
explain the second band. Detection of differentially processed proteins may be the result of increased amount of the EV markers and/or altered biocomposition of EV produced by
cells grown under different bioreactor conditions.
Fig. 2. Biophysical characterization of purified bioreactor EV. (A) Nanoparticle tracking
analysis (NTA) was used to characterize the size of purified EV, as shown in repre-
sentative size frequency distribution plot. Each sample for was run in triplicate at
1e2 mg/mL concentration. Black line represents mean values, and red shaded area
represents SEM. NTA was able to distinguish three main subpopulations based on size
corresponding to peaks of approximately 120, 190, and 280 nm in diameter. (B)
Transmission electron micrograph of bioreactor EV.
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comparison of NTA plots from several preparations of EV from
either method revealed that the size distribution of culture-flask
derived EV was more limited (Fig. S3), which could be a result of
a different mixture of EV subpopulations. Serum-free culture
conditions have previously been reported to affect EV composi-
tion [28], so we further compared the composition of bioreactor
vs. flask EV by comparative proteomics, using mass spectrometry
(Supplementary File 1 and Fig. S4). Many proteins were shared
between the two samples, including EV markers such as CD63,
Alix, and TSG101. However, serum proteins were over-represented
in the flask EV.3.3. Purified bioreactor EV are bioactive in vitro
We used a HEK293 cell clone that expresses the human
membrane-associated heterodimeric interleukin-15 complex, IL-
15:IL-15Ra (hetIL-15) [22,23], to examine whether optimally puri-
fied EV maintain functional hetIL-15 on their surface (Fig. 3A).
D.C. Watson et al. / Biomaterials 105 (2016) 195e205200Given its function as an expander and activator of natural killer and
cytotoxic T-cells [23], IL-15 is being developed as a potential cancer
immunotherapeutic in clinical studies [29]. The presence of EV-
associated hetIL-15 was confirmed by Western blot using anti-
bodies against the two polypeptide chains of hetIL-15, IL-15 and IL-
15Ra (Fig. 3B). Upon surface expression, the full length ~59 kDa IL-
15Ra is cleaved and secreted as a soluble ~42 kDa molecule [23].
Indeed, EV-associated IL-15Rawas mostly of the larger membrane-
associated species, which was also detected in association with cell
lysates (Fig. 3C). Flow cytometric analysis verified that hetIL-15 was
associated with the EV surface (Fig. 3D). The bioactivity of EV-
associated hetIL-15 was confirmed in vitro by using an estab-
lished MTT-based proliferation assay on the human NK-92 cell line.
Upon stimulation by either form of the cytokine (soluble or EV-
associated), NK-92 cells proliferated to a similar degree (Fig. 3E),
indicating that purified EV maintain bioactive properties.
3.4. Scavenger receptor A family (SR-A) mediates EV binding to
monocytes/macrophages
We assessed the contribution of SR-A to EV uptake in vitro by
using dextran sulfate, a molecule known to block this receptor
[30,31]. Chondroitin sulfate was used as a control for any non-
specific activity of dextran sulfate [30,31], as both molecules are
negatively charged carbohydrate polymers. By flow cytometry, we
confirmed that the murine macrophage cell line RAW 264.7 ex-
presses the SR-A1 receptor isoform, while a panel of tumor cell
lines lacks the expression of this receptor (see Supplementary
Fig. S5). In agreement with the SR-A1 expression levels, dextran
pre-treatment of RAW 264.7 cells resulted in a 30e50% decrease in
EV uptake when incubated with fluorescently-labeled EV, whereas
this effect was not observed in the tumor cell lines that lacked SR-
A1 expression (Fig. 4A). Given the contemporaneous report of BLT-1Fig. 3. EV purified from hollow fiber bioreactor and containing surface hetIL-15 retain IL-15 b
the presence of IL-15 cytokine in cell lysate and in bioreactor-derived EV from a HEK293 cell
cell lysate is from parental HEK293 cell line. (C) EV-associated IL-15Ra is primarily membr
apparent molecular weight of the EV-associated protein was compared to that detected in
secreted protein). The majority of EV-associated IL-15Ra is the same size as that of the cell-
vesicular surface. Flow cytometry histograms show signal intensity from EV probed with PE
and probed with fluorophore-conjugated antibody to detect presence of surface cytokine
HEK293 cell clone stably overexpressing the cytokine. (E) EV-associated IL-15 is bioactive in v
as quantified by mean MTT assay O.D in 6 wells per sample (mean ± SEM). Magenta line rep
HEK293 cell clone overexpressing hetIL-15. Black line represents triplicate bioactivity asse
HEK293 cell EV resulted in MTT O.D. <0.25.(a known SR-B1 blocker) blocking EV uptake in macrophages [32],
we combined this molecule with dextran sulfate in the RAW
264.7 cell assay, and found an additive effect of dual scavenger
receptor blockade (Fig. S6).
We also addressed the contribution of SR-A on EV uptake by
human peripheral blood mononuclear cells (PBMC), a heteroge-
neous population of primary human cells. PBMC, pretreated with
dextran sulfate, were exposed to labeled EV, and EV uptake in
different primary cell subsets was monitored by flow cytometry,
using a combination of fluorescently labeled monoclonal anti-
bodies. These experiments demonstrated that most EV were bound
tomonocytes and that 30e60% of this uptake could be abrogated by
SR-A blocking (Fig. 4B).
3.5. SR-A blockade changes biodistribution of administered EV
We tested the hypothesis that blocking SR-A receptors would
impact EV biodistribution by treating mice pretreated with either
dextran sulfate or chondroitin with DiR-labeled EV by tail vein in-
jection. EV biodistribution was monitored by fluorescence imaging
of live mice as well as excised organs. Imaging performed at 2 h
post-injection of EV showed that SR-A blockade decreased liver
uptake of EV by ~50% (Fig. 5). In contrast, SR-A blockade by dextran
sulfate significantly increased the amount of EV circulating in the
plasma (Fig. 5). Thus, blocking the EV receptor SR-A led to signifi-
cant changes in EV biodistribution.
3.6. Tumor accumulation of administered EV is enabled by SR-A
blockade
Next, we assessed whether blocking monocyte/macrophage
uptake results in enhanced tumor accumulation of EV, in the
absence of targeting ligands. Immunocompetent mice bearingioactivity. (A) Schematic representation of EV bearing hetIL-15. (B) Western blot shows
clone that stably overexpresses the IL-15 heterodimer complex (IL-15:IL-15Ra). Control
ane anchored. Western blot of IL-15Ra associated with bioreactor EV preparation. The
the cell lysate (transmembrane protein) and in purified secreted hetIL-15 (truncated,
associated (membrane-anchored) cytokine. (D) EV-associated hetIL-15 is displayed on
-conjugated aIL-15 antibody. EV were first captured on aCD63 antibody-coated beads
. Control EV were derived from parental HEK293 cells and hetIL-15 EV came from a
itro. Bioactivity assessed as proliferation of the NK92 cell line following 72 h incubation,
resents bioactivity of 3 independent EV preparations from bioreactor supernatants of a
ssment of protein standard. Incubation of cells with equal protein amount of control
Fig. 4. EV uptake in monocytes/macrophages is largely mediated by the Scavenger
receptor A family (SR-A). Cells were pretreated with dextran sulfate (SR-A blocker) or
chondroitin sulfate (dextran control) for 30 min. After washing away inhibitor, stained
EV were added for 2 h. Flow cytometry was used to quantify EV uptake by fluorescent
intensity of cells. Boxes represent range of values (min to max), and line in box denotes
group mean. Uptake compared between groups by multiple t-tests, with Holm-Sidak
correction for multiple comparisons (Cumulative alpha-error <0.05). One (*), two
(**), and three (***) asterisks denote p < 0.05, p < 0.01, and p < 0.001, respectively. (A)
Blocking SR-A with dextran sulfate decreased EV uptake by 30e50% only in RAW cells,
and not in cell lines that lack SR-A expression (in three independent experiments).
Viability of cells assessed by Live/Dead fluorescent stain (Invitrogen) showed no effect
of treatment conditions in the tested cell lines (data not shown). (B) Monocytes uptake
the majority of EV among primary human PBMC cultured in vitro, through SR-A (n ¼ 4).
EV uptake was quantified by mean fluorescent intensity above background, and
normalized to EV uptake by untreated monocytes of each donor sample.
D.C. Watson et al. / Biomaterials 105 (2016) 195e205 201subcutaneous 4T1 breast cancer cell tumors were pretreated with
the SR-A blocker, followed by systemic delivery of labeled EV. Im-
aging of live mice over a period of 24 h showed that significant
intratumoral EV accumulation could only be observed in animals
pretreated with dextran sulfate (Figs. 6 and 7), even though SR-A
blockade of the liver diminished over 24 h (Fig. 6C, right panel).
Ex vivomeasurements also showed that EV tumor uptake increased
by ~3-fold over the 24-h period (Fig. 7).4. Discussion
In this study, we developed methods for the purification of
bioactive EV, carrying membrane-embedded heterodimeric IL-15.
These results indicate the presence of a third form of hetero-
dimeric IL-15 in addition to the soluble and the cell membrane-
embedded forms [22,23,33,34]. Presence of functional hetIL-15 on
EV may have significant physiologic roles and implications. It was
previously shown that IL-15 Receptor alpha (the stabilizing
component of hetIL-15) is expressed on EV from cultured human
dendritic cells, which can directly activate NK cells only in thepresence of exogenous recombinant IL-15 (active cytokine
component of hetIL-15) [35]. Contrarily, EV purified from
HEK293 cells expressing hetIL-15 maintain IL-15 bioactivity
without addition of exogenous cytokine, which could be a signifi-
cant benefit when using EV as therapeutics. Furthermore, it re-
mains to be examined whether primary human dendritic cells also
secrete functionally significant EV bearing complete hetIL-15 under
conditions not tested previously (e.g. stimulation by certain toll-
like receptor ligands) [36].
We developed a methodology for the mass production of highly
purified, bioactive EV using a lab-scale hollow fiber bioreactor,
which may facilitate further in vivo studies. This method presents
many advantages over conventional culture that likely contribute to
the higher EV production yield and purity that we observed. First,
lab-scale hollow fiber bioreactors enable the sustained mainte-
nance of large numbers of cells (estimated by the manufacturer to
be in the order of 109 cells) within a standard incubator, with
minimal maintenance. Specifically, a 2 L bottle of medium is simply
replaced every 2 days. More importantly, all of the cultured cells
secrete EV into the relatively small volume of the culture cartridge
extracapillary space (~60 mL) resulting in EV-rich conditioned
medium that can be used directly for EV purification. Our findings
suggest that this method yields 40-fold more EV particles per
volume of conditioned medium vs. conventional cell culture. Thus,
to match a single daily harvest of the hollow-fiber bioreactor
(20 mL), an estimated 53 large (175 cm2) flasks producing 800 mL
conditioned medium would be required. Moreover, cells grown in
hollow-fiber bioreactors readily adapt to sustained growth in
protein-free medium, which also facilitates EV purificationwithout
serum contaminants, as highlighted by our comparative proteomics
study. On the other hand, bioreactor EV preparations may have a
more diverse population of EV, as suggested by the increased size
range. Thus, further purification of preparations (e.g. by density
gradient) may be required for some applications.
Our findings showing the greatly enhanced yield of EV purified
from hollow-fiber cultures may also have significant implications
for the development of clinical grade EV therapeutics, given that
hollow-fiber methods have already been used to expand primary
human cells under cGMP conditions [25,26].
Moreover, we show for the first time that blocking SR-A, a novel
receptor for EV, enables accumulation of even untargeted EV in
several tissues, including tumors (Fig. 8). Our in vitro findings
showed that monocytes/macrophages are uniquely affected by SR-
A blockade with respect to EV uptake. Interestingly, in the mixed
PBMC culture, the blockade of monocyte EV uptake was accom-
panied by an increase in uptake by T-cells, perhaps a result of EV
binding to a different receptor on the latter. In vivo, increased cir-
culation and accumulationwithin tumors coincidedwith decreased
liver uptake, confirming previous findings that liver macrophages
rapidly clear administered EV in the absence of scavenger receptor
blockade [17]. When chondroitin sulfate or dextran sulfate were
administered to mice prior to labeled EV injection, we observed an
increase in splenic uptake of EV compared to mice receiving EV
alone (Fig. 5). A possible explanation for this could be the trafficking
of circulating monocytes to the spleen after uptake of either
negatively charged polymer, as has been described previously for
negatively charged poly(lactic-co-glycolic acid) (PLGA) formula-
tions [37]. At the highest dose of dextran, even though monocytes
are still possibly sequestered in the spleen, their EV uptake capacity
would be largely inhibited, resulting in the lower splenic EV uptake
of this group. In any case, SR-A blockade by dextran sulfate
consistently decreased liver uptake of EV, and significantly
increased their ability to accumulate within tumors.
Considering the massive EV clearance by the RES under physi-
ological conditions, our results are important for EV therapeutic
Fig. 5. SR-A blockade decreases liver clearance of EV. FVB mice were pre-treated with 0.6 mg dextran sulfate, chondroitin sulfate, or PBS. 15 mg DiR-stained EV were then injected
intravenously and mice were imaged 2 h later. (A) Live animal imaging showing dramatically decreased liver uptake of EV with SR-A blocker pre-treatment. (B) Organ bio-
distribution of administered EV changes after SR-A blockade. A representative image of excised organs is shown from each group. Plasma is shown from three different mice of each
group. (C) Quantitation of EV accumulation in excised organs showed decrease of liver uptake, and increase in circulating EV at 2 h in the mice receiving dextran sulfate. Bars
represent group mean þ SEM (n ¼ 3). Uptake was compared between groups using ANOVA, with Turkey correction for multiple comparisons. One (*), two (**), and three (***)
asterisks denote p < 0.05, p < 0.01, and p < 0.001, respectively.
Fig. 6. Kinetics of EV uptake by liver and tumor following single injection of SR-A blocker in subcutaneous 4T1 tumor-bearing Balb/c mice (tumor location indicated by white circle).
Mice were pretreated with either PBS, 0.6 mg dextran or chondroitin, injected IV with 15 mg stained EV, and imaged live at the indicated time points. (A) Serial live animal imaging
showing early inhibition of EV uptake by the liver, and gradual accumulation of EV in the tumor only in mice pre-treated with the SR-A blocker dextran sulfate. (B) Time course of EV
uptake (mean ± SEM) in tumor and liver of 4T1 bearing Balb/c mice (n ¼ 4 per group), analyzed by 2-way ANOVA. Tumor accumulation increases significantly with time in SR-A
blocked mice (left panel), even though liver uptake blockade was transient, following a single injection of dextran sulfate (right panel).
D.C. Watson et al. / Biomaterials 105 (2016) 195e205 203applications. Our findings make the case for developing potent SR-
A blockers with favorable toxicity profiles. Combining scavenger
receptor blockade with EV targeting using relevant ligands may
further improve the targeted delivery of therapeutic RNA, viral
vectors or any other molecules. Given that small molecules and
peptides with the potential to block SR-A and other scavenger re-
ceptors are under development and some are in clinical trials
[38e40], blocking RES uptake in therapeutic settings comprises a
promising approach to enable a broad spectrum of effective EV-
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Fig. 7. Significant EV uptake detected at 24 h in excised 4T1 tumors only from mice pre-treated with the SR-A blocker dextran sulfate. Mice were pretreated with either PBS, 0.6 mg
dextran or chondroitin, and injected IV with 15 mg stained EV. (A) Fluorescence imaging of excised tumors showing increased EV uptake in dextran-pretreated mice. (B) Quantitation
of EV accumulation in excised tumors of SR-A blocked mice, after 24 h. Bars display group mean ± SEM. Uptake compared between groups by ANOVA, with Sidak correction for
multiple comparisons. Three asterisks (***) denote p < 0.001.
Fig. 8. Schematic depiction of the application of SR-A blockade for tumor delivery of EV carrying therapeutic molecules.
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